| Drug ID: | Drug22 |
|---|---|
| Drug Name: | Indigotindisulfonic Acid |
| CID: | 3705 |
| DrugBank ID: | DB11577 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT01914445 |
| Molecular Formula: | C16H10N2O8S2 |
| Molecular Weight: | 422.4 g/mol |
| Isomeric SMILES: | C1=CC2=C(C=C1S(=O)(=O)O)C(=C(N2)C3=NC4=C(C3=O)C=C(C=C4)S(=O)(=O)O)O |
| Synonyms: | INDIGOTINDISULFONIC ACID; Saxon blue; Blue X; Indigo carmine acid; 2-(1,3-Dihydro-3-oxo-5-sulpho-2H-indol-2-ylidene)-3-oxoindoline-5-sulphonic acid; X7OI7JF73P; NSC-8646; 1H-INDOLE-5-SULFONIC ACID, 2-(1,3-DIHYDRO-3-OXO-5-SULFO-2H-INDOL-2-YLIDENE)-2,3-DIHYDRO-3-OXO-; 207-593-7; Indigotindisulfonate |
| Phase 0: | 1 |
| Phase 1: | 2 |
| Phase 2: | 2 |
| Phase 3: | 1 |
| Phase 4: | 3 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt199 | 3705 | Indigotindisulfonic acid | 196 | AHR | Homo sapiens (human) | Indigo carmine binds to and results in increased activity of AHR protein | |
| dt200 | 3705 | Indigotindisulfonic acid | 196 | AHR | Mus musculus (house mouse) | 15001395 | Indigo carmine binds to AHR protein |
| dt201 | 3705 | Indigotindisulfonic acid | 196 | AHR | Homo sapiens (human) | 15882963 | Indigo carmine binds to AHR protein |
| dt202 | 3705 | Indigotindisulfonic acid | 1137 | CHRNA4 | Rattus norvegicus (Norway rat) | 23429044 | [ponceau 4R co-treated with allura red AC dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with tartrazine co-treated with amaranth dye co-treated with brilliant blue co-treated with indigo carmine] |
| dt203 | 3705 | Indigotindisulfonic acid | 1141 | CHRNB2 | Rattus norvegicus (Norway rat) | 23429044 | [ponceau 4R co-treated with allura red AC dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with tartrazine co-treated with amaranth dye co-treated with brilliant blue co-treated with indigo carmine] |
| dt204 | 3705 | Indigotindisulfonic acid | 140634 | cyp1a | Gasterosteus aculeatus (three-spined stickleback) | 21354474 | Indigo carmine results in increased expression of CYP1A mRNA |
| dt205 | 3705 | Indigotindisulfonic acid | 1543 | CYP1A1 | Homo sapiens (human) | 18493746 | Indigo carmine inhibits the reaction [tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]|indigo carmine results in increased activity of CYP1A1 protein |
| dt206 | 3705 | Indigotindisulfonic acid | 1543 | CYP1A1 | Mus musculus (house mouse) | 15882963 | Indigo carmine results in increased expression of CYP1A1 mRNA |
| dt207 | 3705 | Indigotindisulfonic acid | 1543 | CYP1A1 | Rattus norvegicus (Norway rat) | 15001395 | Indigo carmine results in increased expression of CYP1A1 mRNA |
| dt208 | 3705 | Indigotindisulfonic acid | 1545 | CYP1B1 | Gasterosteus aculeatus (three-spined stickleback) | 21354474 | Indigo carmine results in increased expression of CYP1B1 mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
No related literature
You can run management commands to establish drug-literature associations